NIZORAL ANTI-DANDRUFF Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nizoral Anti-dandruff, and what generic alternatives are available?
Nizoral Anti-dandruff is a drug marketed by Kramer and is included in one NDA.
The generic ingredient in NIZORAL ANTI-DANDRUFF is ketoconazole. There are fifteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ketoconazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nizoral Anti-dandruff
A generic version of NIZORAL ANTI-DANDRUFF was approved as ketoconazole by TARO on June 15th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NIZORAL ANTI-DANDRUFF?
- What are the global sales for NIZORAL ANTI-DANDRUFF?
- What is Average Wholesale Price for NIZORAL ANTI-DANDRUFF?
Summary for NIZORAL ANTI-DANDRUFF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Patent Applications: | 1,512 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NIZORAL ANTI-DANDRUFF at DailyMed |
Pharmacology for NIZORAL ANTI-DANDRUFF
| Drug Class | Azole Antifungal |
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors Cytochrome P450 3A5 Inhibitors P-Glycoprotein Inhibitors |
US Patents and Regulatory Information for NIZORAL ANTI-DANDRUFF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kramer | NIZORAL ANTI-DANDRUFF | ketoconazole | SHAMPOO;TOPICAL | 020310-001 | Oct 10, 1997 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NIZORAL ANTI-DANDRUFF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Kramer | NIZORAL ANTI-DANDRUFF | ketoconazole | SHAMPOO;TOPICAL | 020310-001 | Oct 10, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Kramer | NIZORAL ANTI-DANDRUFF | ketoconazole | SHAMPOO;TOPICAL | 020310-001 | Oct 10, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Kramer | NIZORAL ANTI-DANDRUFF | ketoconazole | SHAMPOO;TOPICAL | 020310-001 | Oct 10, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for NIZORAL ANTI-DANDRUFF
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| HRA Pharma Rare Diseases | Ketoconazole HRA | ketoconazole | EMEA/H/C/003906 Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. |
Authorised | no | no | yes | 2014-11-18 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for NIZORAL ANTI-DANDRUFF
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
